2021
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations
Vrachatis DA, Papathanasiou KA, Iliodromitis KE, Giotaki SG, Kossyvakis C, Raisakis K, Kaoukis A, Lambadiari V, Avramides D, Reimers B, Stefanini GG, Cleman M, Giannopoulos G, Lansky A, Deftereos SG. Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations. Drugs 2021, 81: 1381-1395. PMID: 34297330, DOI: 10.1007/s40265-021-01565-3.Peer-Reviewed Original ResearchConceptsAtrial fibrillationSGLT2 inhibitorsCardiorenal protectionAntiarrhythmic effectsClinical dataSodium/glucose co-transporter-2 inhibitorClinical data implyDate available evidenceGlucose-lowering medicationsEffective therapeutic optionPotential pathophysiological linkLarge clinical trialsPre-specified endpointsType 2 diabetesPossible beneficial effectsPost Hoc AnalysisNormoglycemic adultsAF burdenAF preventionPathophysiologic mechanismsPathophysiological linkSGLT2 inhibitionAntiarrhythmic potentialSodium glucoseTherapeutic optionsRefining drug-eluting stent technologies: from engineering to basic science
Lansky A, Chun H, Pietras C, Hussain Y. Refining drug-eluting stent technologies: from engineering to basic science. European Heart Journal 2021, 42: 1770-1772. PMID: 33624813, DOI: 10.1093/eurheartj/ehab091.Peer-Reviewed Original Research
2020
The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent.
Saito Y, Grubman D, Cristea E, Lansky A. The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. Cardiology In Review 2020, 28: 208-212. PMID: 32032131, DOI: 10.1097/crd.0000000000000298.Peer-Reviewed Original ResearchConceptsAbluminal grooveFIREHAWK stentBiodegradable Polymer Sirolimus-Eluting StentLate adverse eventsPercutaneous coronary interventionCurrent clinical evidenceSirolimus-Eluting StentsDrug-eluting stent technologyAdverse eventsCoronary interventionClinical outcomesChronic inflammationClinical evidenceHypersensitivity reactionsRecent trialsDrug concentrationsStent technologyStentsInflammationFIREHAWKReviewSirolimus
2014
Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study)
Kelly CR, Weisz G, Maehara A, Mintz GS, Mehran R, Lansky AJ, Parise H, de Bruyne B, Serruys PW, Stone GW. Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study). The American Journal Of Cardiology 2014, 114: 376-383. PMID: 24931291, DOI: 10.1016/j.amjcard.2014.04.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCoronary AngiographyCoronary Artery DiseaseC-Reactive ProteinDisease ProgressionFemaleGlobal HealthHumansIncidenceInflammationMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSurvival RateTime FactorsConceptsMajor adverse cardiac eventsC-reactive protein levelsNonculprit lesionsElevated CRP levelsCRP levelsVulnerable coronary plaquesIntravascular ultrasoundCoronary plaquesPost-acute coronary syndrome patientsSubsequent major adverse cardiac eventsGray-scale intravascular ultrasoundCoronary Tree (PROSPECT) studyUntreated nonculprit lesionsAdverse cardiac eventsAdverse coronary eventsAcute coronary syndromeCoronary syndrome patientsPercutaneous coronary interventionRadiofrequency intravascular ultrasoundPredictors of eventsProtein levelsMinimal luminal areaHigh rateCoronary eventsCoronary syndrome